Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -87.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.29% |
| Mar 31, 2026 | 64.19% |
| Dec 31, 2025 | 18.55% |
| Sep 30, 2025 | 43.48% |
| Jun 30, 2025 | 100.17% |
| Mar 31, 2025 | -18.51% |
| Dec 31, 2024 | 148.43% |
| Sep 30, 2024 | 75.48% |
| Jun 30, 2024 | 13.05% |
| Mar 31, 2024 | 8.62% |
| Dec 31, 2023 | -25.64% |
| Sep 30, 2023 | 49.35% |
| Jun 30, 2023 | 5.55% |
| Mar 31, 2023 | -59.35% |
| Dec 31, 2022 | 36.31% |
| Sep 30, 2022 | 7.32% |
| Jun 30, 2022 | -32.51% |
| Mar 31, 2022 | 28.61% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -23.99% |